Exhibit 4.1


 


FORM OF PRE-FUNDED COMMON
STOCK PURCHASE WARRANT


 


ORTHOPEDIATRICS CORP.


 


Warrant Shares: [•]


 


Date of Issuance: [•], 2022 (such date,
the “Issue Date”)


Warrant No.: [•]


 


THIS PRE-FUNDED COMMON
STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder
hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on
exercise and the conditions set forth herein, at any time on or after the Issue Date, to subscribe for and purchase from OrthoPediatrics
Corp., a Delaware corporation (the “Company”), up to [•] shares (subject to adjustment hereunder, the
 “Warrant Shares”) of the Company’s common stock, par value $0.00025 per share (“Common Stock”).
The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 3(a).


 


Section 1. Definitions.
For purposes of this Warrant, the following terms shall have the following meanings:


 


	 	(a)	“Affiliate”
    means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
    control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act of 1933, as amended (the
    “Securities Act”).


 


	 	(b)	“Attribution
    Parties” means any Persons and entities whose holdings would be aggregated with the Holder as the same “acquiring
    person” under the rules and regulations promulgated under the HSR Act, as defined in Section 3(d).


 


	 	(c)	“Bloomberg”
    means Bloomberg Financial Markets.


 


	 	(d)	“Business Day”
    means any day except any Saturday, any Sunday, any day that is a federal legal holiday in the United States or any day on which the
    Trading Market is authorized or required by law or other governmental action to close.


 


	 	(e)	“Registration
    Statement” means the Company’s Registration Statement on Form S-3 (File No. 333-237177), that
    became effective on March 27, 2020, and any subsequent registration statements filed pursuant to Rule 462(b) under
    the Securities Act with respect thereto.


 


	 	(f)	“Person”
    means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
    any other entity and a government or any department or agency thereof.


 


	 	(g)	“Trading Day”
    means any day on which the Common Stock is traded on the Trading Market.


 


	 	(h)	“Trading Market”
    means the principal securities exchange or securities market, including an over-the-counter market, on which the Common
    Stock is then traded in the United States.


 


	 	(i)	“Weighted Average
    Price” means, for any security as of any date, the dollar volume-weighted average price for such security on the Trading
    Market during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as
    reported by Bloomberg through its “Volume at Price” function or, if the foregoing does not apply, the dollar volume-weighted
    average price of such security in the over-the-counter market on the electronic bulletin board for such security during
    the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg,
    or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest
    closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the “pink sheets”
    published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices).
    If the Weighted Average Price cannot be calculated for such security on such date on any of the foregoing bases, the Weighted Average
    Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company
    and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 6(n) with
    the term “Weighted Average Price” being substituted for the term “Exercise Price.” All such determinations
    shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during such period
    pursuant to Section 4.


 






     


     


    

 


Section 2. Issuance of Securities.
The Warrant is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are offered
under the Registration Statement. Accordingly, the Warrant and, assuming either (a) an issuance pursuant to the Registration Statement
or (b) an exchange meeting the requirements of Section 3(a)(9) of the Exchange Act is in effect on the Issue Date, the
Warrant Shares, are not “restricted securities” under Rule 144 promulgated under the Securities Act. The Company shall
register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”),
in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is
assigned pursuant to the terms hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as
the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent
actual notice to the contrary.


 


Section 3. Exercise.


 


	 	(a)	Exercise of Warrant.
    Subject to the terms and conditions hereof, the purchase rights represented by this Warrant may be exercised, in whole or in part,
    at any time or times on or after the Issue Date by delivery (whether via facsimile or otherwise) to the Company (or such other office
    or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing
    on the Warrant Register) of a duly executed copy of the Notice of Exercise form annexed hereto (the “Notice of Exercise”)
    and by payment to the Company of an amount equal to the aggregate Exercise Price of the Warrant Shares thereby purchased by wire
    transfer (or by notifying the Company that this Warrant is being exercised pursuant to a Cashless Exercise (as defined below) in
    accordance with Section 3(c) hereof). The aggregate exercise price of this Warrant, except for the nominal
    $0.00025 per share, was pre-funded to the Company on or before the Issue Date, and consequently no additional consideration
    (other than the nominal $0.00025 per share) shall be required by to be paid by the Holder to effect any exercise of this Warrant.
    The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.00025, subject to adjustment hereunder
    (the “Exercise Price”). No ink-original Notice of Exercise shall be required, nor
    shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. The Holder
    shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise
    Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase
    the remaining number of Warrant Shares, if any. The Holder and any assignee, by acceptance of this Warrant, acknowledge and
    agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
    number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.


 


	 	(b)	Mechanics of Exercise.


 


	 	(i)	Delivery of Warrant
    Shares Upon Exercise. Warrant Shares purchased hereunder shall be transmitted to the Holder or its designee by crediting
    the account of the Holder at the Company’s transfer agent or Holder’s or its designee’s prime broker with The Depository
    Trust Company (“DTC”) through its Deposit/Withdrawal at Custodian (“DWAC”) system
    if the Company is then a participant in such system, or if the transfer agent is not participating in the Fast Automated Securities
    Transfer Program (the “FAST Program”) by the date that is two Trading Days after the receipt by the Company
    of the Notice of Exercise (provided that payment of the Exercise Price (or notification of Cashless Exercise, if applicable) has
    then been received by the Company) (such date, the “Warrant Share Delivery Date”). This Warrant shall be
    deemed to have been exercised upon proper delivery of the Notice of Exercise and payment of the Exercise Price (or notification of
    Cashless Exercise) in accordance with the terms hereof. Upon delivery of the Notice of Exercise, the Holder shall be deemed for all
    corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised,
    irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (or notification
    of Cashless Exercise, if applicable) is received on the same Trading Day as the Notice of Exercise. The Company shall use its reasonable
    best efforts to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and
    exercisable.


 






     -2-


     


    

 


	 	(ii)	Delivery of New Warrant
    Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon
    surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
    the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
    respects be identical with this Warrant.


 


	 	(iii)	Compensation for Buy-In on
    Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the
    Company fails to cause its transfer agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 3(b)(i) above
    pursuant to an exercise on or before the Warrant Share Delivery Date (other than a failure caused by incorrect or incomplete information
    provided by the Holder to the Company), and if after such date the Holder is required by its broker to purchase (in an open market
    transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction
    of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
    then the Company shall either (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase
    price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
    by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the
    exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, or (B) at
    the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
    was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
    that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if
    the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
    exercise of this Warrant with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of
    the immediately preceding sentence the Company shall be required to pay the Holder $1,000. Nothing herein shall limit a Holder’s
    right to pursue a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver
    Warrant Shares upon exercise of the Warrant as required pursuant to the terms hereof.


 


	 	(iv)	No Fractional Shares
    or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.
    As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at
    its election, either pay a cash adjustment in respect of such final fractions in an amount equal to such fraction multiplied by the
    Exercise Price or round up to the nearest whole share.


 


	 	(v)	Charges, Taxes and Expenses.
    Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in
    respect of the issuance of such shares, all of which taxes and expenses shall be paid by the Company, and such shares shall be issued
    in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that
    in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered
    for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require,
    as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall
    pay all transfer agent fees required for any Notice of Exercise and all fees to the DTC (or another established clearing corporation
    performing similar functions) required for electronic delivery of the Warrant Shares.


 


	 	(vi)	Closing of Books.
    The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant pursuant
    to the terms hereof.


 






     -3-


     


    

 


	 	(c)	Cashless Exercise.
    Notwithstanding anything contained herein to the contrary, the Holder may exercise this Warrant, whether in whole or in part, and
    in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Exercise
    Price, by effecting a cashless exercise of this Warrant pursuant to which the Holder shall receive upon such cashless exercise the
    “Net Number” of Warrant Shares determined according to the following formula (a “Cashless Exercise”):


 


Net Number =        (A
x B) - (A x C)


B


 


For purposes of the foregoing formula:


 


	 	A	= the total
    number of shares of Common Stock with respect to which this Warrant is then being exercised.


 


	 	B	= the Weighted
    Average Price of the shares of Common Stock on the date immediately preceding the date of the Notice of Exercise.


 


	 	C	= the Exercise
    Price then in effect for the applicable Warrant Shares at the time of such exercise.


 


If Warrant Shares are issued in
such a Cashless Exercise, the Company acknowledges and agrees that in accordance with Section 3(a)(9) of the Securities Act,
the Warrant Shares shall take on the registered characteristics of the Warrant being exercised, and the holding period of the Warrant
being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to
this Section 3(c).


 


	 	(d)	Holder’s Exercise
    Limitations. In the event that a purported exercise of this Warrant would result in the Holder acquiring beneficial ownership
    of Warrant Shares (together with all other equity of the Company owned by the Holder at such time) with a value of or in excess of
    the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), notification threshold
    applicable to the Holder (the “HSR Threshold”), and no exemption to filing a notice and report form under
    the HSR Act is applicable, then the Warrant will be deemed to have been exercised on the later date that is immediately following
    the date of the expiration of the HSR waiting period.  In addition, Holder covenants and agrees to exercise this Warrant
    as soon as practicable following, but in no event later than five (5) Business Days following: (i) the expiration of the
    HSR waiting period or (ii) the exercise of the Warrant otherwise becoming exempt from a notification thereunder.
	 	 	 
	 	(e)	Notwithstanding anything to the
                                    contrary contained in any section herein, the Company agrees to comply with any applicable rules of
                                    the Trading Market with respect to the issuance of the Warrant Shares to the Holder and to take any
                                    action required by such rules to issue such Warrant Shares.



 


Section 4. Certain Adjustments.


 


	 	(a)	Subdivision or Combination
    of Common Stock. During such time as this Warrant is outstanding, if the Company subdivides (by any stock split, stock
    dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares,
    the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares
    will be proportionately increased. During such time as this Warrant is outstanding, if the Company combines (by combination, reverse
    stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise
    Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will be
    proportionately decreased. Any adjustment under this Section 4(a) shall become effective at the close of business
    on the date the subdivision or combination becomes effective.


 






     -4-


     


    

 


	 	(b)	Subsequent Rights Offerings.
    In addition to any adjustments pursuant to Section 4(a) above, if during such time as this Warrant is outstanding
    the Company grants, issues or sells any rights to purchase stock, warrants, securities or other property, in each case pro rata to
    the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will
    be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have
    acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
    to any limitations on exercise hereof) immediately before the date on which a record is taken for the grant, issuance or sale of
    such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be
    determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to
    participate in any such Purchase Right would result in the Holder and the other Attribution Parties collectively beneficially owning
    in excess of the HSR Threshold, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
    ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent
    shall be held in abeyance for the Holder until such time, if ever, as its right thereto would either not result in the Holder and
    the other Attribution Parties exceeding the HSR Threshold or any HSR waiting period has expired).


 


	 	(c)	Pro Rata Distributions.
    During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets
    (or rights to acquire its assets) to holders of any class of shares of Common Stock, by way of return of capital or otherwise (including,
    without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
    corporate rearrangement, scheme of arrangement or other similar transaction) (other than as a result of a stock dividend covered
    by Section 4(a) above) (a “Distribution”), then, in each such case, the Holder shall
    be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder
    had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
    on exercise hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken,
    the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution
    (provided, however, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder
    and the other Attribution Parties exceeding the HSR Threshold, then the Holder shall not be entitled to participate in such
    Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such
    extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as
    either its right thereto would not result in the Holder and the other Attribution Parties exceeding the HSR Threshold or any
    HSR waiting period has expired).


 






     -5-


     


    

 


	 	(d)	Fundamental Transaction.
    If, at any time while this Warrant is outstanding (i) the Company, directly or indirectly, in one or more related transactions,
    effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity
    or the stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least
    50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii) the Company, directly or
    indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition to another Person of all or substantially
    all of its assets in one or a series of related transactions, (iii) any direct or indirect purchase offer, tender offer or exchange
    offer (whether by the Company or another Person) is completed pursuant to which holders of capital stock who tender shares representing
    more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts
    such tender for payment, (iv) the Company, directly or indirectly, in one or more related transactions, consummates a stock
    purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or
    scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the voting power of the capital stock
    of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain,
    in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v) the Company,
    directly or indirectly, in one or more related transactions, effects any reclassification, reorganization or recapitalization of
    the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
    other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 4(a) above)
    (in any such case, a “Fundamental Transaction”), then following such Fundamental Transaction the Holder
    shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would
    have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental
    Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any
    limitations on exercise contained herein (the “Alternate Consideration”). For purposes of any such exercise,
    the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount
    of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall
    apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different
    components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property
    to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it
    receives upon any exercise of this Warrant following such Fundamental Transaction. Any such payment of such amount of such Alternative
    Consideration shall be made in the same form of consideration (whether securities, cash or property) as is given to the holders of
    Common Stock in such Fundamental Transaction, and if multiple forms of consideration are given, the consideration shall be paid to
    the Holder in the same proportion as such consideration is paid to the holders of Common Stock. The terms of any agreement pursuant
    to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with
    the provisions of this paragraph (d) and insuring that this Warrant (or any such replacement security) will be similarly
    adjusted upon any subsequent Fundamental Transaction. The Company shall not effect any Fundamental Transaction in which the Company
    is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration
    is solely cash and the Company provides for the simultaneous “cashless exercise” of this Warrant pursuant to Section 3(c) or
    (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person
    (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration
    as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant.
    The provisions of this paragraph (d) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction
    type.


 


	 	(e)	Calculations.
    All calculations under this Section 4 shall be made to the nearest cent or the nearest whole share, as the
    case may be. For purposes of this Section 4, any calculation of the number of shares of Common Stock deemed to be
    issued and outstanding as of a given date shall not include treasury shares, if any.


 


Section 5. Transfer of Warrant.
Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer
of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer
taxes (if any) by the Holder. Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form
of this Warrant (any such new warrant, a “New Warrant”) evidencing the portion of this Warrant so transferred
shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall
be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such
transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company
shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company’s own expense any New Warrant under this Section 5.
Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all
purposes, and the Company shall not be affected by any notice to the contrary.


 


Section 6. Miscellaneous.


 


	 	(a)	No Rights as Stockholder
    Until Exercise. Except as expressly set forth in Section 4, this Warrant does not entitle the Holder
    to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 3.
    In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities
    (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company
    or by creditors of the Company.


 






     -6-


     


    

 


	 	(b)	Loss, Theft, Destruction
    or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to
    them of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in
    case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and cancellation of
    such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor
    and dated as of such cancellation, in lieu of such Warrant or stock certificate.


 


	 	(c)	Saturdays, Sundays,
    Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
    or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding
    Business Day.


 


	 	(d)	Authorized Shares.
    The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
    Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under
    this Warrant (without regard to any limitations on exercise contained herein). The Company further covenants that its issuance of
    this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute
    and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
    will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
    violation of any applicable law or regulation, or of any requirements of the Trading Market. The Company covenants that all Warrant
    Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase
    rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued,
    fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other
    than taxes in respect of any transfer occurring contemporaneously with such issue). Except and to the extent as waived or consented
    to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or
    through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary
    action (including any Fundamental Transaction), in each case, avoid or seek to avoid the observance or performance of any of the
    terms of this Warrant, and will at all times in good faith assist in the carrying out of all such terms and in the taking of all
    such actions as may be necessary or appropriate to protect the rights of the Holder as set forth in this Warrant against impairment.
    Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
    the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as
    may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
    upon the exercise of this Warrant and (iii) use its reasonable best efforts to obtain all such authorizations, exemptions or
    consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations
    under this Warrant. Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant
    is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto,
    as may be necessary from any public regulatory body or bodies having jurisdiction thereof. The Company covenants to list the Warrant
    Shares on the Trading Market on or prior to the issuance date of this Warrant.


 


	 	(e)	Governing Law.


 


	 	(i)	This Warrant shall be governed
    by, and construed in accordance with, the law of the State of New York without giving effect to any choice or conflict of law provision
    or rule (whether of the State of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction
    other than the State of New York.


 


	 	(ii)	Each of the Company and
    the Holder irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of the courts of
    the State of New York sitting in the Borough of Manhattan, New York and of the United States District Court of the Southern District
    of New York, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Warrant and
    the transactions contemplated herein, or for recognition or enforcement of any judgment, and each of the Company and the Holder irrevocably
    and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York
    state court or, to the fullest extent permitted by applicable law, in such federal court. Each of the Company and the Holder hereto
    agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit
    on the judgment or in any other manner provided by law.


 






     -7-


     


    

 


	 	(iii)	Each of the Company and
    the Holder irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any objection that it may now
    or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Warrant and the transactions
    contemplated herein in any court referred to in Section 6(e)(ii) hereof. Each of the Company and the Holder
    hereby irrevocably waives, to the fullest extent permitted by applicable law, the defense of an inconvenient forum to the maintenance
    of such action or proceeding in any such court.


 


	 	(iv)	EACH OF THE COMPANY AND
    THE HOLDER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY
    JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS WARRANT OR THE TRANSACTIONS CONTEMPLATED HEREBY
    (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH OF THE COMPANY AND THE HOLDER (A) CERTIFIES THAT NO REPRESENTATIVE,
    AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT
    OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT EACH OF THE COMPANY AND THE HOLDER HAS BEEN INDUCED
    TO ENTER INTO THIS WARRANT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.


 


	 	(f)	Nonwaiver and Expenses.
    No course of dealing or any delay or failure to exercise any right hereunder on the part of the Holder shall operate as a waiver
    of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this
    Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
    damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
    but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting
    any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.


 


	 	(g)	Notices.


 


	 	(i)	Notice Procedures.
    Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
    shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
    via email or facsimile at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the
    date of transmission, if such notice or communication is delivered via email or facsimile on a day that is not a Trading Day or later
    than 5:30 p.m. (New York City time) on any Trading Day, (c) the second Trading Day following the date of mailing, if sent
    by U.S. nationally recognized overnight courier service or by International Federal Express, (d) the third Trading Day following
    the date of mailing if sent by first-class registered or certified mail domestic, or (e) upon actual receipt by the party to
    whom such notice is required to be given. The addresses for such communications shall be:


 


If to the Company:


 


OrthoPediatrics
Corp.


2850 Frontier
Drive


Warsaw, Indiana
46582


United States
of America


	 	Attention:	David Bailey, Chief Executive Officer







Daniel Gerritzen,
General Counsel and Vice President of Legal


	 	Email:	dbailey@orthopediatrics.com; dgerritzen@orthopediatrics.com



 






     -8-


     


    

 





With copy
to:


 


Dentons Bingham
Greenebaum LLP


2700 Market
Tower


10 W. Market
Street


Indianapolis, Indiana
46204


United States
of America


	 	Attention:	Jeremy E. Hill, Esq.; Bradley C. Arnett, Esq.
	 	Email:	jeremy.hill@dentons.com; bradley.arnett@dentons.com



 


If
to the Holder:


 


To
the address, email address or facsimile number set forth in the Warrant Register, or as otherwise provided by the Holder to the Company
in accordance with this Section 6(g)(i).


 


	 	(ii)	Adjustment to Exercise
    Price. Whenever the Exercise Price or number of Warrant Shares is adjusted pursuant to any provision of Section 4,
    the Company shall promptly provide the Holder a notice setting forth the Company’s good faith adjustment of the Exercise Price
    and number of Warrant Shares after such adjustment and setting forth a description of the transactions giving rise to such adjustments
    and a detailed statement of the facts upon which such adjustment is based.


 


	 	(iii)	Notice to Allow Exercise
    by the Holder. After the Issue Date, if (A) the Company shall declare a dividend (or any other distribution in whatever
    form) on the Common Stock, including any Distribution, (B) the Company shall declare a special nonrecurring cash dividend on
    or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights
    or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, including any Purchase Right,
    (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common
    Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets
    of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, including
    any Fundamental Transaction, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
    up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last address as it
    shall appear upon the Warrant Register, at least ten calendar days prior to the applicable record or effective date hereinafter specified,
    a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights
    or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to
    such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
    consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is
    expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities,
    cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that
    the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action
    required to be specified in such notice. The Holder shall remain entitled to exercise this Warrant during the period commencing on
    the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth
    herein.


 






     -9-


     


    

 


	 	(h)	Limitation of Liability.
    No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares,
    and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
    price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of
    the Company.


 


	 	(i)	Remedies.
    The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
    to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
    for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
    the defense in any action for specific performance that a remedy at law would be adequate. Without limiting any rights of a Holder
    to receive Warrant Shares on a “cashless exercise” pursuant to Section 3(c) herein or to receive
    cash payments pursuant to Section 3(b)(iii), in no event shall the Company be required to net cash settle an exercise
    of this Warrant.


 


	 	(j)	Successors and Assigns.
    Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of
    and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of the Holder. The
    provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
    by the Holder or holder of Warrant Shares.


 


	 	(k)	Amendment.
    This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.


 


	 	(l)	Severability.
    Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
    law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
    to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
    of this Warrant.


 


	 	(m)	Dispute Resolution.
    In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company
    shall submit the disputed determinations or arithmetic calculations in writing within two Business Days of receipt of the Notice
    of Exercise giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to agree upon
    such determination or calculation of the Exercise Price or the Warrant Shares within three Business Days of such disputed determination
    or arithmetic calculation being submitted to the Holder, then the Company shall, within two Business Days submit in writing (i) the
    disputed determination of the Exercise Price to an independent, reputable investment bank selected by the Company and approved by
    the Holder or (ii) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent, outside accountant.
    The Company shall cause, at its expense, the investment bank or the accountant, as the case may be, to perform the determinations
    or calculations and notify the Company and the Holder of the results no later than ten Business Days from the time it receives the
    disputed determinations or calculations. Such investment bank’s or accountant’s determination or calculation, as the
    case may be, shall be binding upon all parties absent demonstrable error. The expenses of the investment bank and accountant will
    be borne by the Company unless the investment bank or accountant determines that the determination of the Exercise Price or the arithmetic
    calculation of the Warrant Shares by the Company was correct and such determination by the Holder was incorrect, in which case the
    expenses of the investment bank and accountant will be borne by the Holder.


 


	 	(n)	Headings.
    The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
    Warrant.


 


[remainder of page intentionally
left blank]


 






     -10-


     


    

 


IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date
first above indicated.


 


	 	ORTHOPEDIATRICS CORP.



 


	 	By:	
	 	Name:	David R. Bailey
	 	Title:	President and Chief Executive
    Officer


 


[Signature Page to
Pre-Funded Warrant]


 






     


     


    

 


NOTICE OF EXERCISE


 


To: OrthoPediatrics Corp.


 


	(1)	The undersigned holder of Warrant No.                  hereby
    elects to purchase                  Warrant
    Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of
    the exercise price in full, together with all applicable transfer taxes, if any.


 


	(2)	Payment shall take the form of (check applicable box):


 


	 	 ̈	Cash Exercise: lawful money
    of the United States; or


 


	 	 ̈	Cashless Exercise: the
    cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in Section 3(c),
    to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
    set forth in Section 3(c).


 


	(3)	Please issue said Warrant Shares in the name of the
    undersigned or in such other name as is specified below:


 


	 	 	 
	 	 	 	 



 


	(4)	By its delivery of this Notice of Exercise, the undersigned
    represents and warrants to the Company that in giving effect to the exercise evidenced hereby, the Holder, together with the other
    Attribution Parties, will not beneficially own in excess of the HSR Threshold or any HSR waiting period has expired, each as defined
    in the Warrant to which this notice relates.


 


The Warrant Shares shall be delivered to
the following DWAC Account Number or by delivery by book entry on the transfer accounts records to:


 


	 	 	 
	 	 	 	 



 


	 	 	 
	 	 	 	 



 


	 	 	 
	 	 	 	 



 


	
	 	Name
    of Holder



 


	 	By:	
	 	Name:	
	 	Title:	
	 	Date:	


 






     


     


    

 


ASSIGNMENT FORM


 


(To assign the foregoing
warrant, execute


this form and supply
required information.


Do not use this form
to exercise the warrant.)


 


FOR VALUE RECEIVED, [                ]
all of or [            ] shares of the foregoing Warrant and all rights evidenced
thereby are hereby assigned to


 


	 	 






whose
address is:




 


	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 



 


	Dated:	 	 




 


	Holder’s Signature:	 	 
	 	 	 
	Holder’s Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 




 


NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration
or enlargement or any change whatsoever.